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ABSTRACT 
VALIDATION OF A NEW ANATOMIC SEVERITY GRADING SYSTEM FOR 
ACUTE CHOLECYSTITIS.   
Kenneth Vera B.S. and Kevin Y. Pei M.D. Section of General Surgery, Trauma, and 
Surgical Critical Care, Department of Surgery, Yale University School of Medicine, New 
Haven, CT. 
The American Association for the Surgery of Trauma (AAST) established 
anatomic grading in 2015 to facilitate risk stratification and risk adjusted outcomes in 
emergency general surgery.  This study validates the AAST anatomic grading system for 
acute cholecystitis (AC) at a tertiary, academic referral medical center.   
This is a retrospective cohort study of 315 patients admitted for AC between 2013 
and 2016.  Cholecystitis severity was graded based on clinical, imaging, operative, and 
pathologic criteria in accordance with the published AAST anatomic grading scale.  
Grade I is acute cholecystitis, grade II is gangrenous or emphysematous cholecystitis, 
grade III is localized perforation, grade IV and V have regional and systemic peritonitis 
respectively.  There was very good interrater (2 independent raters) reliability for 
anatomic grading, κ=1.00, p<0.005. 
Concordance between the AAST grade and outcomes including mortality, length 
of stay (LOS), ICU use, and adverse events was assessed using statistical methods.  
Incidence of complications, LOS, ICU use, and any adverse event increased with 
increasing anatomic grade.  When compared to grade I disease, patients with grade II 
were more likely to undergo cholecystectomy (Odds Ratio 4.07 [1.93-8.56]), require ICU 
use (Odds Ratio 2.41 [1.31 – 4.44]) and develop a complication (Odds Ratio 2.07 [1.22 – 
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3.53]).  Grade III patients were at higher risk of adverse events (Odds Ratio 3.83 [1.34-
10.94]) and ICU use (Odds Ratio 8.07 [2.43-26.80]).   
In conclusion, AAST severity grading scores were independently associated with 
clinical outcomes in patients with AC.  Despite most patients having low grade disease, 
complications were common.  Therefore, a refinement of the scoring system for 
cholecystitis may be necessary for more granular prediction of outcomes at milder levels 
of disease. 
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INTRODUCTION 
Surgeons routinely care for patients with acute cholecystitis (AC).  The 
prevalence of gallstones is approximately 10-20% of US adult population and a third will 
develop cholecystitis.  Laparoscopic cholecystectomy (LC) is one of the most common 
surgical procedures, but complexity and outcomes of surgery depend on disease severity.  
To that extent, the American Association for the Surgery of Trauma (AAST) introduced 
an anatomic severity grading system for emergency general surgery (EGS) diseases in 
2014 (1).  This objective and uniform system for quantifying anatomic severity has been 
proposed for use in research as well as clinical settings.  Such a system facilitates 
standardized communication of severity in patient management, quality studies, outcome 
comparisons, and provider to provider discussion.  The AAST anatomic severity grading 
system has yet to be validated to patient outcomes for many EGS diseases.  The purpose 
of this investigation was to validate the system for a cohort of patients admitted to Yale-
New Haven Hospital with AC. 
The AAST Scoring System 
The AAST anatomic severity grading system is based on the Organ Injury Scale 
(OIS) developed in the 1990’s by a designated committee within the AAST.  The 
committee was charged with developing a set of standardized grading scales from 1-5 for 
traumatic injuries to internal organs based on their anatomic description.  These organ-
specific scales were formed from expert opinion and subsequently proposed for use in 
clinical research (2) and have since been validated in numerous studies following their 
introduction.  The AAST scoring system was designed in a similar fashion in 2015.  A 
literature review of all existing scoring systems for individual EGS diseases was 
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performed and a uniform grading system that can be applied to all EGS diseases was then 
agreed upon by expert consensus (1). 
As of 2016, emergency general surgery care accounts for approximately 7% of all 
hospitalizations in the US.  The national average cost of a hospitalization and operation 
for an EGS disease is $10,744 with the total number of EGS hospitalizations in the US 
costing over 28 billion dollars annually.  These figures are projected to increase by 45% 
by 2060 (3).  Standardization of disease severity affords the opportunity to compare 
outcomes from various general surgical procedures across different medical centers in the 
US when adjusted for comorbid conditions and disease complexity.  The need for 
standardized assessment is particularly critical in the current era of outcome-based 
practice in many facets of medicine.  Incorporating a uniform system for describing 
disease into the field of emergency general surgery may ultimately lead to improved 
outcomes and quality of care. 
Criteria-based scoring systems have previously been developed for medical and 
surgical diseases including those in EGS.  One notable example is the Hinchey score, a 
radiographic severity grading system, for diverticulitis.  The very first such scale for 
cholecystitis was published by a group from Tokyo in 2007 and most recently revised in 
2018 (4).  Although these and other scales are used across the world for a range of 
clinical and research purposes, the AAST scale is the first to have been designed 
specifically for use in the field of emergency general surgery.   
The AAST advocates its grading system’s wide spectrum of disease severity, its 
ease of use, and intuitive application.  The grading system is designed to be uniformly 
applied across a diverse range of EGS diseases.  Furthermore, it only incorporates 
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anatomical data into the grading scale and excludes physiological parameters or patient 
comorbidities (1).  As the physiological severity of a disease is more often secondary to 
its anatomic severity, an anatomically focused grading system is better utilized when 
evaluating patient outcomes due to a primary disease process.  This is a potential benefit 
of AAST over existing grading systems such as the Tokyo system. 
The AAST severity scores were not only adopted from the OIS but were also 
based on the TNM system used for staging various types of cancers (1).  Both TNM and 
AAST incorporate gradients from local to wide spread of disease in the range of their 
grading.  AAST grades I and II are both limited to the organ and are associated with mild 
or severe abnormality, respectively.   Grades III-V represent anatomical progression from 
localized to regional to widespread disease (5).  The grading is also consistent with 
respect to the progression from modest to severe inflammation.  The range of this scale 
encompasses almost the entire severity spectrum of any EGS disease.  Subsequent studies 
validating the scale have adopted a score of 0 for “normal” findings described in 
pathology or imaging on retrospective review.   
Validation of the AAST Scoring System 
The AAST scoring system uses clinical, imaging, operative, and pathological data 
to grade the anatomic severity of disease on a scale from 1-5, with 5 being the most 
severe.  In their most recent report, the AAST provides how the scale can be applied to 
individual EGS diseases with 16 diseases described (6).  The AAST has advocated for 
validation studies using this system to assess its level of applicability to EGS diseases and 
the outcomes of patients diagnosed with and admitted for management of the disease.  To 
date, there have been a handful of validation studies in diseases such as diverticulitis and 
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small bowel obstruction.  These studies include both single and multi-center retrospective 
studies.   
One of the first published studies validating the AAST scale for EGS diseases was 
published in 2015 (7).  The study aimed to investigate the association between AAST 
score and patient outcomes in a retrospective cohort of 512 patients admitted with acute 
colonic diverticulitis at a single center.  The AAST grades for colonic diverticulitis were 
independently associated with adverse outcomes after controlling for patient co-
morbidities.  Furthermore, there were no systemic differences in grade assignment 
between two graders.  A multicenter study including a cohort of 1,105 patients with 
diverticulitis from 13 centers was subsequently published by the same investigative group 
and again demonstrated an association of disease grade with adverse outcomes and a high 
level of interrater reliability (8). 
A recent report validated the AAST anatomic severity grading scale for 
appendicitis in a population of 334 patients at a single center (9).  Their study showed a 
significant correlation between severity score and complications including length of stay 
(LOS) as well as conversion from a laparoscopic to open operation.  Within their cohort, 
11.8% of patients with AAST grade 0-2 disease developed a complication versus 54.2% 
of patients with grade III-V disease.  This was the first report validating the AAST 
scoring system for predicting any outcome in appendicitis.  In a single-center 
retrospective review of 1,099 appendectomies including at least 40 cases from each 
AAST severity grade, the AAST was validated to predict symptom duration, 
appendectomy duration, as well as cost of care (10). 
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Baghdadi et al published the first report validating the AAST for small bowel 
obstruction (11).  They studied a retrospective cohort of 351 patients with partial or 
complete small bowel obstruction using both the original AAST scoring system and a 
modified version of the AAST system incorporating patient physiology and comorbidities 
using SIRS criteria and Charlson comorbid scores.  The authors argue that physiology is 
an inherent part of disease, particularly in the management of patients with small bowel 
obstruction, and therefore should be primarily incorporated into disease assessment.  
Both the AAST and modified scores showed significant associations between greater 
disease severity and greater inpatient complications and extended LOS.  However, 
neither was superior in predicting these endpoints.  Despite a low mortality rate in their 
cohort, their modified score better predicted mortality than AAST. 
The Tokyo Guidelines (TG) for cholecystitis incorporates anatomical findings as 
well as multiple physiological parameters into its approach to diagnosis and severity 
assessment.  As described in their 2018 revision, grade I or “mild” disease is classified as 
cholecystitis in a healthy patient who has no findings of organ dysfunction.  Grade II or 
“moderate” disease is characterized as having marked inflammation of the gallbladder.  
Criteria for grade II disease includes elevated white blood cell count, a tender and 
palpable right upper quadrant mass, and duration of disease for 72 hours or more.  Grade 
III (“severe”) disease is moderate severity accompanied by evidence of organ dysfunction 
(4).   
The TG has been studied in multiple retrospective cohorts and revised to correct 
limitations to its validation.  Furthermore, it has evolved from a tool used in research to a 
guideline for management and clinical judgement based on disease severity.  The 
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management component of the guideline recommends early cholecystectomy with 
adjuvant antibiotic therapy for grade I disease and conservative approaches including 
medical management with percutaneous cholecystostomy tube in grades II and III (4).  A 
similar path of evolution is ideally how AAST may become usefully incorporated into the 
field of emergency general surgery.  However, the distinction between TG and AAST 
grading is an important one.  Only the anatomic severity of disease contributes to the 
AAST grade whereas the inclusion of physiologic parameters in TG may complicate its 
ability to compare pure primary disease across patients. 
Although physiological variables are significant predictors of outcomes 
themselves, statistically controlling for the patient’s physiological state at admission 
allows the association between anatomic disease severity and patient outcomes to more 
accurately be analyzed.  Comorbid conditions such as smoking and hypertension and 
social determinants of health such as ethnicity and insurance status can likewise be 
controlled for their effect on outcomes.  Such an analysis has been consistently 
incorporated into published studies validating AAST scales.  The AAST scoring system 
was designed to assess the extent to which anatomic severity predicts outcomes.  It 
cannot be determined whether a scale incorporating physiological parameters better 
predicts outcomes than one based solely on anatomical severity without first validating 
the AAST. 
Introduction to Cholecystitis 
The clinical presentation of cholecystitis, including its severity and range of 
associated complications, can vary within a given patient population.  Gallstones are by 
far the most common cause of cholecystitis, followed by stenosis of the biliary tract (12).  
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AC may be managed either medically or surgically with a laparoscopic cholecystectomy 
(removal of the gallbladder and its contents) being the most common operation used for 
treatment (13).   
Pathologically, cholecystitis occurs as a result of both cystic duct obstruction and 
damage to the gallbladder mucosa.  Gallstones may become impacted in the neck of the 
gallbladder of the cystic duct and cause mechanical mural irritation as the result of the 
gallbladder contracting against the stone.  Damage to the mucosa leads to the release of 
phospholipases from the epithelial cells lining the gallbladder lumen.  Phosopholipase A 
catalyzes the production of lysolecithin from lecithin, a normal component of bile.  
Lysolecithin further irritates the epithelial lining of the gallbladder and mural distension 
and edema leads to epithelial vascular insufficiency.  This damage leads to continued 
phospholipase release from damaged epithelial cells and propagates the inflammatory 
reaction causing AC (12).  Due to the stasis of bile proximal to the obstruction at the neck 
of the gallbladder, its contents are more prone to a superimposed bacterial infection.  
Infection of the gallbladder, and uncommonly the whole biliary system, may complicate 
the disease although only 20% of patients with cholecystitis grow a pathogen in bile 
cultures (12). 
The formation of gallstones is complex and involves an interplay between 
secretions of cholesterol into the bile, bile stasis secondary to gallbladder dysmotility, and 
crystal nucleation of stones.  Oversaturation of bile with cholesterol and low levels of bile 
salts enhance stone formation.  Age, female gender, obesity, oral contraceptives, parity, 
North American Indian ancestry, and consuming a western diet have all been found to be 
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associated with increased risk of gallstones in various studies.  Dyslipidemia is also risk 
factor and more than 80% of gallstones are cholesterol based (13).   
Biliary colic is a steady right upper quadrant or epigastric abdominal pain that 
lasts for more than 30 minutes but less than 4 hours.  It is sudden in onset and usually 
occurs following consumption of a fatty meal.  It is caused by an intermittent obstruction 
of the gallbladder neck or the cystic duct by gallstones during gallbladder contraction.  In 
most instances, colic resolves during gallbladder relaxation as the stone falls back.  
However, sustained obstruction of the cystic duct can lead to bile stasis, gallbladder 
distension with mucosal and endothelial injury, and subsequent activation of 
inflammatory mediators leading to AC (14). 
Gallstones are highly prevalent in western populations with some studies 
reporting prevalence rates as high as 10-15% in adult populations (15).  However, some 
estimated 1-4% of patients with gallstones will go on to have any serious complications 
such as cholecystitis.  Furthermore, most patients with gallstones are completely 
asymptomatic, with multiple studies reporting digestive symptoms in just less than 10% 
of populations positive for sonographic gallstones (14).  However, rates of cholecystitis 
in this population of patients with symptomatic stones have been reported to be as high as 
15% (15).  Most gallstone-related complications including cholecystitis can be prevented 
with cholecystectomy and thus elective cholecystectomy may be indicated for patients 
with frequent digestive symptoms. 
Acalculous cholecystitis is pathologically identical to AC but not caused by 
gallstones.  It accounts for approximately 10% of all cases of AC and usually occurs in 
hospitalized patients who are critically ill (16).  Pro-inflammatory conditions such as 
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cancers, infections, or trauma can lead to gallbladder ischemia or promote bile stasis.  
This can lead to gallbladder endothelial damage which initiates the same 
pathophysiological cascade seen in calculous cholecystitis.  The clinical features of 
acalculous cholecystitis more often include jaundice, hyperbilirubinemia and elevation of 
liver transaminases.  Patients with acalculous cholecystitis have been observed to have 
higher morbidity and mortality rates; this may be partially explained by the comorbid 
inflammatory process acalculous cholecystitis may present with (16).   
Diagnosis of Cholecystitis 
Understanding the diagnosis of cholecystitis is fundamental to evaluating the 
severity of the disease.  Traditionally, the diagnosis of cholecystitis has been made based 
on clinical suspicion supported by lab data and confirmed with imaging findings.  
Clinical features of the disease include abdominal pain, nausea, vomiting, fever, 
Murphy’s sign (abrupt cessation of inspiratory effort due to elicited pain), and right upper 
quadrant or epigastric abdominal tenderness with or without guarding (12).  The 
differential diagnosis is wide and may also include hepatitis, pancreatitis, peptic ulcer 
disease, gallbladder cancer, or Fitz-Hugh-Curtis syndrome. 
There are no specific blood tests used to make the diagnosis of AC.   However, 
laboratory tests can be used to support the diagnosis and/or exclude other etiologies of 
pain.  Common tests used include white blood cell count, serum bilirubin, lipase levels, 
and liver transaminase levels (12).   
Imaging studies used in the diagnosis include abdominal ultrasound and 
cholescintigraphy.  Ultrasonography is the initial imaging modality of choice as it is 
11	  
	  
rapid, taking only minutes to perform, and inexpensive to use.  Findings consistent with 
AC include gallbladder wall thickening (>4 mm), gallbladder distension, pericholecystic 
fluid collections, and pericholecystic fat stranding (17).  A meta-analysis of 30 studies on 
imaging studies for gallbladder disease found the sensitivity and specific of ultrasound 
for diagnosing cholecystitis to be 88% and 80%, respectively (18).  A more recent meta-
analysis of 57 studies found the sensitivity and specificity to be 81% and 83% 
respectively (17). 
Cholescintigraphy, also referred to as a HIDA (Hepatobiliary Iminodiacetic) scan, 
may be used to aid in the diagnosis if strong clinical suspicion is present in the context of 
an equivocal or indeterminate ultrasound.  This study traces the uptake of a technetium 
labeled acid administered intravenously to a patient and selectively taken up by 
hepatocytes before being excreted into the bile.  Prolonged uptake due to cystic duct 
obstruction indicates a positive study.  Though more sensitive and specific than an 
ultrasound, at 96% and 90% respectively, the HIDA scan takes hours to perform and 
utilizes more sophisticated personnel and equipment than ultrasound.  Additionally, it 
provides data solely relevant to gallbladder pathology and is therefore less useful than 
ultrasound in examining the liver as an alternative source of right upper quadrant 
abdominal pain (17). 
Complications of Cholecystitis 
Early diagnosis and intervention of AC is important to prevent complications 
associated with higher morbidity and mortality.  Gangrenous cholecystitis is a more 
severe and complicated form of the disease characterized by necrosis secondary to 
ischemia and prolonged inflammation of the gallbladder.  Gangrenous cholecystitis is 
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considered grade II on the AAST scale.  It is more common in patients with greater 
comorbidities, such as the elderly and diabetics, and patients with a delayed presentation 
(19). 
Though uncommon, transmural perforation of the gallbladder may occur leading 
to localized abscess formation.  This would be grade III disease in the AAST severity 
scale.  Spillage of gallbladder contents such as pus or bile into the peritoneal cavity may 
cause subsequent generalized peritonitis, AAST grade IV disease.  In rare cases, a biliary-
enteric fistula may form between the gallbladder and small bowel.  Gallstone ileus occurs 
when gallstones passed through a biliary-enteric fistula become lodged in the distal small 
bowel, most commonly the ileum, and cause obstruction.  Sepsis and multiple organ 
dysfunction are more likely complicate the patient’s clinical status during these 
complications (19).  Such a severe case of cholecystitis would be considered grade V on 
AAST. 
Emphysematous cholecystitis is caused by an intramural or intraluminal infection 
of the gallbladder with gas producing organisms.  The most commonly isolated offending 
pathogens include Clostridium perfringens, Escherichia coli, and Klebsiella.  
Emphysematous cholecystitis more commonly affects men, elderly, and diabetic patients.  
It is also associated with higher rates of perforation and a mortality rate of up to 15% 
(19). 
Management of Cholecystitis 
Management of cholecystitis can range from conservative to operational.  
Conservative approaches to the disease include a course of intravenous antibiotics 
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accompanied by supportive care including intravenous fluids, pain control, and 
electrolyte correction.  The most common pathogens covered by empiric antimicrobial 
therapy include gram negative rods, particularly Escherichia coli, and anaerobes.  The 
laparoscopic approach to cholecystectomy is associated with decreased morbidity and 
mortality as well as shorter LOS.  The conversion rates to open surgery are low (13).    
The optimal timing of an LC following AC is still an active area of investigation.  
Higher complication rates following surgery in the acute setting are a concern as 
increased local inflammation may obscure the critical view and dissection of Calot’s 
triangle.  Because of this concern, some surgeons elect to manage a patient medically in 
the acute setting and delay surgery for up to six weeks, even in an otherwise 
uncomplicated case (20).  However, large population-based analyses and recent meta-
analyses of case-control studies have shown that early LC in the acute setting is superior 
to delayed LC, with no differences in complication rates and shorter LOS (20, 21).  
However, early cholecystectomy was associated with longer operating times, presumably 
due to increased inflammatory changes in the acute setting.  Despite the significance of 
these findings, these studies do not incorporate anatomic severity of disease in their 
analysis due to the lack of a widely adopted scale such as the AAST. 
Reports using the TG severity scale also favors early cholecystectomy.  A recent 
meta-analysis shows that early cholecystectomy can be a feasible treatment alternative to 
conservative management for AC in carefully selected candidates with TG grade II and 
III disease (22).  In a separate investigate report, Loozen et al also found no statistically 
significant differences in conversion rates, operating time, perioperative complication 
rate, and 30-day mortality between patients with TG grade I and grade II cholecystitis 
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undergoing emergent LC (23).  A separate retrospective analysis on a group of 149 
patients undergoing emergent LC for AC determined that TG severity grade alone did not 
predict whether a patient underwent LC or percutaneous cholecystostomy tube.  Those 
patients undergoing LC experienced longer LOS though did not experience increased 
morbidity or mortality (24).  Another recent study did not show statistically significant 
differences in complication or conversion rates across TG classification although the 
classifications did correlate with LOS (25).  While agreeing that early cholecystectomy 
should be more widely considered in patients with more severe disease but fewer 
comorbidities, these reports also recommend further stratification between grade I and 
grade II disease be considered in future TG revisions. 
A percutaneous cholecystostomy tube (PCT) is a safe and effective intervention 
widely used as a bridging therapy for AC.  It is essentially a catheter which drains the 
gallbladder contents, placed into the lumen via an ultrasound guided transhepatic 
approach.  A PCT can provide relief of cholecystitis symptoms for up to 91% of patients 
undergoing the procedure (26).  It is indicated in patients with severe disease, those with 
contraindications to general anesthesia, those who present >72 hours after symptoms 
onset, or patients failing medical therapy.  Additionally, they are recommended for 
elderly patients with multiple co-morbidities who would have a higher likelihood of a 
safe and successful LC at some time interval following medical management and 
cholecystostomy placement, usually 6-8 weeks.  The disadvantage of this therapy is that 
rates of tube dysfunction are high with up to 46% of patients experiencing some sort of 
dysfunction and over half of these patients requiring re-intervention (26).   
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In elderly patients with multiple chronic comorbidities, PCT may be the only safe 
feasible intervention available as the risks of surgery would outweigh the long-term 
benefits.  Percutaneous gallbladder aspiration has been advocated as an easy to perform 
and less invasive alternative therapy to PCT for patients failing initial medical 
management.  It also avoids drain-related symptoms of discomfort reported by many 
patients discharged with a PCT.  Percutaneous aspiration has also been shown to provide 
comparable outcomes to PCT in retrospective studies as well as randomized controlled 
trials and is recommended in cases where PCT may not be available (27, 28).   
Statement of Purpose and Hypothesis 
The purpose of this original investigation was to retrospectively validate the 
AAST anatomic severity grading system using a cohort of patients admitted to a single, 
tertiary, high volume center with cholecystitis.  A few single center studies have been 
published demonstrating independent associations between severity grades and outcomes 
in diverticulitis and appendicitis.  To our knowledge and to the extent of the published 
literature, there has not been a similar investigation concerning the outcomes of patients 
with cholecystitis.  
Because the AAST grading system was designed to be uniformly applied across a 
variety of EGS diseases, we expect to see associations like those previously reported for 
other EGS diseases.  However, finding a lack of association with the current grading 
system would also be equally valuable in gaining insight into how it may be adjusted to 
fit the range of severity specific to cholecystitis.   Given the current understanding of 
cholecystitis and the validation of AAST in other surgical diseases, we hypothesize that 
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the AAST anatomic severity grade in cholecystitis may independently predict higher 
likelihood of adverse clinical outcomes. 
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METHODS 
This was a retrospective single center cohort study undertaken by Kenneth Vera, medical 
student, and Kevin Y. Pei MD at Yale University School of Medicine.  This study was 
approved by the Human Investigation Committee. 
Inclusion Criteria 
All patients over eighteen years of age who were admitted to Yale-New Haven 
Hospital between August 2013 and August 2016 with a diagnosis of ‘acute cholecystitis’ 
(575.0 or K81.0), ‘acute on chronic cholecystitis’ (575.12 or K81.2), or ‘cholecystitis 
unspecified’ (575.10 or K81.9) based on ICD-9 and ICD-10 codes were included in this 
study.  Patients were excluded if they were a pregnant, a prisoner, or had advanced 
directives limiting care.  They were additionally excluded if they had a prior admission 
for AC within 90 days.  In cases where a patient had multiple admissions for AC on 
record, the data and management from their index admission was used.  Patients were 
excluded if their index admission made note of a recent prior admission for cholecystitis 
at another facility or prior admission for cholecystitis at our facility prior to 2013 as 
records were not available for access in these cases.  Patient who were primarily admitted 
to a medical or surgical floor for some other condition but were subsequently admitted as 
an EGS consult patient were included so long as they received a new diagnosis of AC or 
acalculous cholecystitis (rather than a flare of known chronic cholecystitis) and were 
managed as such.  Cases of patients in severely critical condition found to have acute 
acalculous cholecystitis on imaging within 24-72 hours prior to expiration were excluded. 
 
18	  
	  
Data Collection 
Demographic data collected for each patient included their age, gender, ethnicity, 
and insurance status (categorized as either commercial or public).  This data was 
collected from the electronic medical records (EMR).  All other data extraction was 
performed by a detailed manual review of individual admission records. 
The presence or absence of common co-morbidities was noted based on data in 
their admission notes and past diagnoses noted elsewhere on record.  Our comorbidities 
of interest included whether a patient has is a present smoker, has diabetes, a history of 
progressive renal insufficiency or failure, hypertension, chronic dyspnea, or is on chronic 
steroids or immunosuppressant medications.  Additionally, whether a patient had two or 
more SIRS criteria present at admission and/or was septic based on 2016 Sepsis-3 criteria 
was noted and counted as a comorbidity (29).   
A Sequential Organ Failure Assessment (SOFA) score was calculated based on 
the patient’s worse physiological parameters within the initial 24 hours of admission to 
the emergency general surgery (EGS) service.  We included this score as a covariate in 
our analyses to control for the effect of physiology on outcomes.  Scores were calculated 
as described in the literature and SOFA score component data was available for all 
patients (30).  Patients breathing on room air were calculated as having 21% FiO2.  
Patients documented to be on supplemental oxygen had approximate FiO2 calculated 
based on published conversion formulas.  Approximate PaO2 was calculated from 
documented SaO2 from published conversion formulas (31).  GCS was assumed to be 15 
unless otherwise noted on documented physical exam.  In cases where the patient 
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received an operation within the first 24 hours of admission, the worse parameters prior 
to surgery were used.   
The outcomes of interest included LOS, whether a patient received operative 
management, if they had a complication while admitted, readmission within 30 days, and 
ICU use (defined as at least 12 hours of admission to a medical or surgical ICU).  
Complications of interest included surgical wound infection or disruption, acute renal 
failure, transfusion of blood products during admission, mechanical ventilation for more 
than 48 hours, and diagnosis of UTI, pneumonia, or DVT/PE during admission, septic 
shock requiring vasopressors, and cardiac arrest or myocardial infarction.  Operative 
management was cholecystectomy, either index or interval, performed for the indication 
of AC.  Mortality data was also collected and based on death being reported during the 
patient’s hospital stay or within 30 days after discharge if readmitted.   
Specific data was additionally collected from the operative records of those 
patients who had surgery.  This was done to better relate the surgical complexity of this 
cohort subset although this data is not included in statistical analysis. This data included 
the interval of time between presentation to the hospital and the beginning of the patient’s 
operation, the operation time of day and its duration, as well as the training level of the 
assisting surgical resident. 
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AAST Grading 
Data extraction and disease severity grading were performed by two independent 
researchers.  AAST grades were assigned to each patient based on clinical, operative, 
pathological, and imaging criteria, with a composite of four grades for each of these 
criteria.  A detailed grading rubric adapted from the AAST’s published 2015 report is 
reproduced below (6).  The final grade assigned was the highest of any criteria.  For those 
patients who did not have a cholecystectomy, either index or interval, only clinical and 
imaging criteria were available.  Grading was based on manual review of data available 
in the patient’s EMR including admission history and physical exam, progress notes, as 
well as pathology, operative and imaging reports.  Pathological grades were recorded for 
both patients with index cholecystectomy as well as interval cholecystectomy performed 
within 3-12 weeks of conservative management for their index admission of AC.  
Interrater reliability of grade assignment was assessed using kappa coefficient with 
Fleiss-Cohen quadratic weights. 
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AAST Anatomic Severity Grading Scale as published in Shafi et al 2015. 
 
Clinical Criteria Imaging Criteria Operative Criteria Pathological Criteria 
Grade 
I 
RUQ or 
epigastric pain, 
Murphy sign, 
Leukocytosis 
Wall thickening, 
distension, 
gallstones or sludge, 
pericholecystic 
fluid, non-visualized 
GB on HIDA 
Localized 
inflammation, wall 
thickening, 
distension, 
gallstones 
Inflammatory changes 
without necrosis or 
pus 
Grade 
II 
RUQ or 
epigastric pain, 
Murphy sign, 
Leukocytosis 
Air in GB lumen, 
wall or biliary tree.  
Focal mucosal 
defects 
Distended GB with 
pus or hydrops, 
necrosis/gangrene of 
wall (non-
perforated) 
Pus in the GB lumen, 
wall necrosis, 
intramural abscess, 
epithelial sloughing 
Grade 
III 
Localized RUQ 
peritonitis 
Focal transmural 
defect, extraluminal 
fluid collection 
Perforated GB wall, 
bile outside GB but 
limited to RUQ 
Necrosis with 
perforation of the GB 
wall 
Grade 
IV 
Multifocal 
peritonitis, 
abdominal 
distension, bowel 
obstruction 
symptoms 
Abscess in RUQ 
outside of GB, 
bilioenteric fistula, 
gallstone ileus 
Pericholecystic 
abscess, bilioenteric 
fistula, gallstone 
ileus 
Necrosis with 
perforation of the GB 
wall 
Grade 
V 
Generalized 
peritonitis 
Free intraperitoneal 
bile 
Generalized 
peritonitis 
Necrosis with 
perforation of the GB 
wall 
 
Statistical Analysis 
Binary logistic regression analysis was used to model the associations between 
AAST grades and their covariate predictors with the occurrence of clinical events.  AAST 
grade was included as an ordinate independent variable with grade I used as the reference 
for comparisons of other severity grades.  Separate logistic regression models were made 
for each clinical event.  C-statistic values were calculated and used for goodness-of-fit 
comparisons among the models.   
A negative binomial regression model was used to measure the association of 
covariate predictor variables and AAST grade with LOS as a continuous dependent 
variable.  To enforce normality and equal variance assumptions to the negative binomial 
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regression analysis, an interpretation of the original output data was performed where all 
data points with Standardized Pearson Residual absolute values > 2 were considered 
outliers and excluded from a second otherwise identical regression model.  This excluded 
11 data points from the original set of 315.  The Akaike’s Information Criteria (AIC) and 
Bayesian Information Criterion (BIC) values pre- and post-outlier exclusion were used 
for goodness-of-fit comparison where smaller-is-better assumptions were applied to 
accept the new model.  These were 1532 and 1569 for AIC and BIC after outlier 
exclusion, compared to 1667 and 1705 originally. 
In all models, age and SOFA score were both continuous predictive variables 
while sex, race/ethnicity, public insurance status, and presence of comorbidities were 
nominal variables.  Male sex, non-minority race/ethnicity, having commercial insurance, 
and having no comorbidities were the respective reference conditions.  The comorbidities 
of interest included those described in the data collection as well as having met SIRS or 
sepsis criteria at admission.  Statistical Analysis was performed with IBM SPSS v.22 
statistical software. 
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RESULTS  
A final set of 315 patients was included in data analysis.  A breakdown of 
demographic, LOS and morbidity data is shown in Table 1.   
Table 1: Patient Demographics and Morbidity   
Average age 61.5 Average LOS [SD] 5.1 days [5.6] 
Minority race/ethnicity* 32% Median LOS [IQR] 3 days [2-6] 
Female 55% ICU use  71 (22%) 
Commercial Insurance 38% Average ICU days [SD] 1 [3.47] 
Government Insurance 60% SIRS or Sepsis 146 (46%) 
Uninsured 2% 
  	         
 *Defined as self-identifying as black or hispanic (non-white) 
A breakdown of disease severity by final AAST grade is shown in Table 2.  
Notably, nearly 94% of cases were grade I or grade II.  No cases meeting grade IV were 
identified and only three were identified as grade V.  There was very good interrater 
reliability between two independent reviewers for anatomic grading, κ=1.00, p<0.005.   
 
 
 
 
The prevalence for each of our comorbidities of interest is shown in Table 3.    
The most common co-morbidities were hypertension, diabetes, and hyperlipidemia.  The 
prevalence for each of our complications of interest is shown in Table 3.  The most 
common complications were acute renal injury (AKI), transfusion, or readmission.  
 
Table 2: AAST Grade Distribution         
Grade       Number of Patients         Percentage 
I 219 (69%) 
II 75 (25%) 
III 18 (5%) 
IV 0 - 
V 3 (1%) 
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Table 3: Prevalence of the Most Common Patient Comorbidities 
Hypertension 171 (54%) 
Diabetes 83 (26%) 
Current smoker 49 (16%) 
Steroids/immunosuppressed 12 (4%) 
Coagulopathy 21 (7%) 
ESRD or CKD 42 (13%) 
Chronic dyspnea 64 (20%) 
Hyperlipidemia 121 (38%) 
Coronary artery disease 59 (19%) 
 
A breakdown of interventions for the patient cohort is shown in Table 4.  
Approximately 49% of patients underwent successful LC during their admission with 
another 13% undergoing interval LC following medical management or a PCT.  
Approximately 32% of patients did not undergo an operation either during their 
admission or after their discharge, the majority (75%) of this subgroup of patients were 
managed with PCT.  Conversion from laparoscopic to open surgery was rare and 
occurred in 7.6% of all operative cases.  In two cases, a patient had an open 
cholecystectomy performed during an exploratory laparotomy.  Two patients, both with 
grade II disease, experienced either cystic duct injury or bile leak as a complication. 
  Table 4: Most Common Interventions 
Medical management 26 8% 
Laparoscopic 
cholecystectomy 153 49% 
Percutaneous 
cholecystostomy 77 24% 
Interval laparoscopic 
cholecystectomy 41 13% 
Laparoscopic converted 
to open cholecystectomy 16 5% 
Open cholecystectomy 2 <1% 
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The average time from hospital presentation to time of cholecystectomy for those 
patients receiving LC during their index admission was 25.2 hours (standard deviation of 
20.9 hours).  Approximately 13% of patients underwent interval LC following medical 
management or a PCT.  The average time from the date of admission for cholecystitis to 
date of cholecystectomy for those patients was 67 days (standard deviation of 45 days).  
Almost all of these operations involved trainees in a seven-year academic general surgery 
residency with the average post-graduate year of training being 4.6 years (standard 
deviation of 1.7 years) for the resident trainees scrubbed into the procedure.  
Approximately 74% of all operations occurred between the hours of 0700 and 1700.  The 
average operation length was 105 minutes (standard deviation of 42 minutes). 
Table 5 shows the incidence of clinical events by final AAST grade.  The 
proportional incidence of any complication, adverse event (defined as either death or 
readmission), ICU use, and median LOS trended upward with increasing severity grade.  
Note that complications in this table are listed as a composite outcome.  Table 6 shows a 
breakdown of the complications observed.  The most common complications were acute 
kidney injury, readmission within 30 days and receiving a blood product transfusion.   
Table 5: AAST Grade and Clinical Events   
 
Grade I Grade II Grade III Grade V 
 
n=219 n=75 n=18 n=3 
Complications 70 (32%) 37 (49%) 12 (67%) 2 (67%) 
Surgery 142 (65%) 58 (77%) 10 (56%) 2 (67%) 
ICU Use 34 (16%) 23 (31%) 12 (67%) 2 (67%) 
30d readmission 31 (14%) 6 (8%) 7 (58%) 2 (67%) 
Median LOS (IQR) 3 (1-5) 4 (2-7) 6.5 (5-8) 11 
Any adverse event 90 (41%) 39 (52%) 15 (83%) 3 (100%) 
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Table 6: Most Common Complications 
Wound infection 6 3% 
Acute kidney injury 77 24% 
Transfusion 37 12% 
Urinary tract infection 24 8% 
Pneumonia 20 6% 
Deep venous 
thromboembolism or 
pulmonary embolus 
7 2% 
Septic shock 28 9% 
Cardiac arrest 16 5% 
Mechanical ventilation 29 9% 
30-day readmission 45 14% 
Death 24 8% 
 
Table 7 shows the association between the included covariates and clinical events 
reported in Odds Ratio (Incidence Risk Ratio for LOS).  Age independently predicted the 
occurrence of a complication and the occurrence of non-operative management.  
Increasing age was also associated with a greater incidence of longer LOS.  SOFA score 
independently predicted higher incidence of a complication, ICU use, non-operative 
management, and occurrence of an adverse event (readmission or death).  The presence 
of any comorbidity predicted ICU use during admission.  Female sex, minority race, and 
having public insurance were largely non-predictive of the outcomes of interest except 
for public insurance status predicting non-operative management.  
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Table 7: Association Between Clinical Events and Predictors 
      Reported as Odds Ratios with 95% CIs (Incidence Risk Ratios with 95% CIs for LOS 
Predictor Complications LOS Surgery ICU Use Adverse Event 
Age 1.04 (1.02 - 1.06)* 
1.01 (1.00 - 
1.02)* 
0.96 (0.94 - 
0.97)* 1.02 (1.00 - 1.04) 1.01 (0.99 - 1.03) 
Female sex 0.90 (0.52 - 1.57) 0.87 (0.67 - 1.13) 
1.05 (0.60 - 
1.84) 0.65 (0.33 - 1.28) 1.39 (0.75 - 2.57) 
Minority 
race 1.83 (0.95 - 3.5) 
1.06 (0.78 - 
1.44) 
0.89 (0.47 - 
1.71) 1.83 (0.82 - 4.05) 1.93 (0.98 - 3.83) 
Public 
insurance 1.18 (0.66 - 2.09) 
1.26 (0.96 - 
1.64) 
0.55 (0.31 - 
0.98)* 1.22 (0.60 - 2.49) 1.11 (0.59 - 2.09) 
SOFA 1.73 (1.44 - 2.09)* 
1.14 (1.07 - 
1.23)* 
0.68 (0.58 - 
0.79)* 1.83 (1.51 - 2.21) 1.44 (1.24 - 1.67)* 
Comorbidity 1.73 (0.78 - 3.80) 1.39 (0.98 - 1.97) 
1.44 (0.68 - 
3.09) 6.1 (1.3 - 28.74)* 1.37 (0.57 - 3.28) 
C-statistic 0.83 (0.78 - .88) N/A 0.80 (0.75 - 0.85) 0.88 (0.84 - 0.92) 0.77 (0.71 - 0.84) 
*Statistically significant finding with p < 0.05.    
 
Table 8 shows the risk-adjusted associations between AAST grade and the 
occurrence of clinical events reported as Odds Ratios (Incidence Ratio for LOS) with 
grade I as the reference range.  Grade II disease was associated with four times the odds 
of operative management.  Grade III disease was associated with almost four times the 
odds of an adverse event (readmission or death) and over eight times the odds of ICU 
use.  Grade III disease was also associated with higher incidence of longer LOS.  
Although grade V disease appeared to be associated with greater odds of complications 
or ICU use, these were not statistically significant.  The notable width of the grade V 
confidence intervals is likely explained by the small size of the group in our sample.  All 
three cases of grade V disease experienced death and the odds ratio of this grade having 
an adverse event is not reportable as there is no variability in the outcome. 
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Table 8:  Risk-Adjusted Association Between AAST and Clinical Events 
     Reported as Odds Ratios with 95% CIs (Incidence Risk Ratios with 95 % CIs for LOS 
Outcome Grade I Grade II Grade III Grade V 
Adverse Event† Ref 0.58 (0.26 - 1.27) 3.83 (1.34 - 10.94)* - 
Complications Ref 1.52 (0.80 - 2.89) 2.22 (0.70 - 7.06) 3.09 (0.23 - 41.41) 
Surgery Ref 4.07 (1.93 - 8.56)* 1.34 (0.45 - 4.03) 1.02 (0.08 - 12.75) 
ICU Use Ref 1.86 (0.87 - 4.01) 8.07 (2.43 - 26.90)* 8.37 (0.65 -107.92) 
Length of Stay Ref 1.06 (0.78 - 1.44) 1.73 (1.03 - 2.92)* 1.03 (0.60 - 1.78) 
*Statistically significant finding with p < 0.05. 
†Either death or readmission within 30 days 
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DISCUSSION 
This is the first single-center study designed to validate the AAST severity 
grading system for cholecystitis.  Our results show that higher grades of severity, notably 
grade III in our sample, is independently associated with multiple patient outcomes after 
controlling for covariate predictors such as age, sex, and physiological status.   
A great majority of patients in our population had low grade disease with 94% 
percent of our population having grade I or grade II disease.  Notably, there were no 
patients with grade IV disease included in our data set.  Although the AAST scale from I-
V offers a rating for a wide range of severity, our data reflect a common clinical 
observation that cholecystitis tends to be milder disease associated with low overall rates 
of mortality.  This reflects the modern era where we are diagnosing and managing 
cholecystitis earlier with the widespread adoption of sensitive imaging techniques for 
diagnosis and less invasive modalities for treatment (32).  The implications for AAST are 
that the current scale for AC may need to be modified prior to being further validated in 
larger samples. 
Other recent studies validating AAST grading scales report a similar finding of 
low-grade disease being over-represented in their retrospective data sets.  Savage et al 
reported 74% of their 512 patient cohort with diverticulitis to have had grade I or II 
disease (7).  Hernandez et al reported 78% of their 334 patient cohort with appendicitis to 
have grade I or II disease (9).  Shafi et al reported two thirds of their 1,105 multicenter 
patient cohort to have had grade I or II disease (8).  Collins et al reported 91% of their 
1,099 patient cohort with appendicitis to have grade I-III disease.  This 
overrepresentation presents a potential challenge for validation of the current scales.  It 
30	  
	  
has been proposed by Shafi et al that oversampling patients with severe disease, 
especially in multicenter studies, would better select a cohort representing the spectrum 
of disease severity.  In our study, patients with severe disease meeting eligibility criteria 
were included in the analysis but it was also observed that patients with higher severity 
scores more often met exclusion criteria.   
An alternative to oversampling patients with severe disease would be to modify 
the current scale such that it more discretely classifies low-grade disease while 
consolidating the higher grades together.  As the scale is currently designed, each of the 
five levels of severity is distinguishable from others anatomically and a gradient of 
morbidity follows accordingly.  For instance, gallbladder perforation is grade III by 
definition.  Because perforation more often leads to localized abscess or peritonitis, the 
step up from grade II to grade III is intuitively associated with increased morbidity and 
mortality.  However, perforation leading to peritonitis is a rare event and most of the 
patients in our cohort cluster in grades I and II.  Increasing resolution of the grading 
system at this mild end of the scale may allow the AAST grading of cholecystitis to better 
fit the spectrum of naturally occurring disease and thus make the tool to more clinically 
meaningful.  We expect the milder spectrum of severity seen in our patient cohort to be 
similar to the range of disease encountered in a larger, multicenter study.  Additionally, 
consolidation of the high-grade scores could be considered to simplify the existing AAST 
system given the rarity of severe grade IV and V disease. 
Interestingly, the occurrence of complications was not significantly associated 
with AAST grade, unlike in reports validating AAST for other EGS diseases.  Although 
an explanation for this is not clear from our data, this endpoint may again be better 
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validated after inclusion of cases of higher grade severity.  We assessed the same 
outcomes as those recorded in large database registries such as the American College of 
Surgeons (ACS) National Surgical Quality Improvement Project (NSQIP).  Outcomes 
such as sepsis, deep vein thrombosis, and pneumonia may not be as applicable to low risk 
procedures such as LC.  In general, complications arising from cholecystectomy, 
particularly when laparoscopic, is rare (33).  The confidence interval width for the 
complications associations, as well as others, suggests a degree of uncertainty in our data 
that is yet to be resolved. 
Hernandez et al argues that the AAST scoring systems would be easier validated 
for the mortality end-point in diseases with greater odds of death (9).  Our data would 
agree with this theory as death was rare in our data set, only occurring in 24 of our 315 
patients.  Only a single death was noted in the 1,105 diverticulitis patients included in 
Shafi et al and therefore was not an analyzed nor validated outcome in their work (8).  
The higher rate of death in our smaller data set may be due to inclusion of admitted 
patients diagnosed with acalculous cholecystitis who have greater morbidity from other 
causes.  Future analysis of our data would consider excluding or separating this subtype 
of patients, further necessitating the inclusion of high grade cases in larger samples of 
patients. 
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Imaging Scores for AAST Grade 
Many of the criteria proposed in the original AAST severity scale for appendicitis 
rely on intraoperative and postoperative pathological findings and thus cannot be utilized 
pre-operatively to predict need for operative management.  Validation of the AAST scale 
as a tool which grades severity without operative or pathological information would make 
the scale useful tool in a real time clinical setting where making decisions with limited 
information is custom.  Hernandez et al therefore proposed that an imaging based AAST 
grade, I-AAST, be first validated (8). 
The I-AAST used by Hernandez et al assigned an anatomic severity grade of I-V 
based on objective CT findings including the size of appendiceal thickening, presence of 
periappendiceal edema, free intraperitoneal fluid, or presence of a localized abscess or 
phlegmon.  A score of 0 was to indicate an appendix which appears normal on CT.  They 
then compared the I-AAST grade with the final AAST reported from operative and 
pathological findings.  They found no significant mean difference between the scores and 
had a coefficient of repeatability of 0.9 on Bland-Altman analysis and an ordinal [kappa] 
coefficient of 0.73 (95% CI, 0.64-0.81) on sensitivity analysis (8).  These findings 
support a strong correlation between I-AAST and the final AAST grades. 
A similar comparison between an imaging based AAST score and the final AAST 
can be made for cholecystitis using ultrasound findings.  Some limitations will be 
expected, however. Ultrasound findings in cholecystitis may be more subjective and open 
to interpretation than CT findings for appendicitis.  There is no standard imaging severity 
for cholecystitis and this may perhaps be a worthy subject of future study.  Anatomical 
parameters, such as millimeters of wall thickening, are less consistently reported in 
33	  
	  
sonographic assessments for cholecystitis.  This may be because it is more difficult to 
accurately assess.  Furthermore, the quality of ultrasound images would be expected to 
vary based on technique and patient factors and be less consistent than the quality of 
images obtained in cross section CT scanning performed for appendicitis.  Nonetheless, 
the AAST imaging scale warrants validation for cholecystitis for the same reasons 
addressed by Hernandez et al in their study on appendicitis.  This is a future aim of this 
body of work. 
Refining the AAST Scale 
The currently proposed AAST scores include a component of the grade based 
purely on clinical criteria, such as presence or absence of fever, abdominal tenderness 
and peritoneal signs (6).  The utility of this component must be considered given that the 
AAST’s intention is to have an anatomically based scale for disease severity.  
Furthermore, the clinical component fails to consider the possible complexity of the 
disease presentation.   
For instance, a patient who is septic from a pneumonia may develop acalculous 
cholecystitis secondary to the inflammation and shock associated with their respiratory 
disease.  While their clinical criteria would meet a grade V score, their gallbladder 
findings on ultrasound may only meet a grade I score.  This discrepancy may ultimately 
be overlooked as the AAST recommend final scores be the highest of the component 
scores.  Although such a complex presentation of AC such as this would likely have 
increased complications associated with a higher score, these complications would not be 
primarily due to the patient’s gallbladder disease.   
34	  
	  
The validation of this component of the scale must then be considered separately 
from imaging, operative, and pathology based scores, as was done in Hernandez et al.  A 
future analysis of clinically based AAST may be performed after first validating imaging 
based AAST scores with final pathological and operative grades for cholecystitis.  
Excluding the clinical component of the scale entirely may be considered given that it is 
the most inherently subjective of the four components.  Furthermore, it may prove to be 
an unnecessary component should the imaging based grades better correlate with the 
pathological grades.   
Limitations 
The data presented in this work is from 315 patients admitted to a single academic 
center over the last 3 years.  A larger, multicenter population of patients with AC is still 
needed to make a more widely generalizable validation the AAST scale.  This work is 
also retrospective and is subject to inherent limitations from this design.  Notably, our 
AAST grading may be affected by information bias as we are applying a new scale to 
existing data on a disease.  Because the records on our patients did not have the AAST 
scale in mind when created, the anatomical descriptions in our records must be fit to the 
descriptions in the scale.  Misclassification of patient’s severity grade may therefore 
occur based on misinterpretation of descriptions.  This bias may be avoided in future 
prospective studies which deliberately record AAST grades in patient records. 
Future Directions 
The refinement of our patient sample is an important future direction.  The use of 
ICD codes is sensitive enough to capture all the cases of interest but the exclusion criteria 
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may not be specific enough.  Excluding cases of admitted patients diagnosed with 
cholecystitis would allow the tool to better assess acute calculous cholecystitis.  
However, this exclusion would be weighed against a loss of statistical power in our 
whole sample and make the grading scale validations less generalizable to in-patients 
who often have acalculous cholecystitis.  At many medical centers the same EGS service 
providers admit patients with cholecystitis whether they are presenting to the emergency 
department or admitted to the floor (32).  Given a large enough sample, separate analyses 
between the two patient types may distinguish which AC patients the AAST is best used 
for and what management approaches are most appropriate. 
The inclusion of two reviewers to have a comparison between two sets of AAST 
grades provides valuable insight into the reliability and ease of using the grading system.  
Future studies on the concordance of multiple reviewers’ scores would benefit in 
determining how precise the instrument is across providers at different medical centers 
and across providers and trainees with varying levels of experience.  As previously 
mentioned, we would ideally like to validate the AAST scores based on imaging against 
the AAST scores based on operatory and pathological findings.  Finally, we are interested 
in analyzing whether it’s the imaging, clinical, operative, or pathological findings which 
most often determine final AAST scores.   
Future outcomes based research using the AAST scale may be valuable after 
validation of the scale to common outcomes included in this report.  As previously 
mentioned, the timing of cholecystectomy for AC is an active area of investigation.  
Investigating the association between AAST grade with the difficulty, duration and 
timing of surgery may be valuable in identifying which patients most benefit from early 
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cholecystectomy.  Such data may also be used to validate the AAST as a system to guide 
management.   
The mapping of EGS disease severity from existing ICD-9 and ICD-10 codes is 
an important future direction for research in AAST.  This involves capturing AAST 
severity grades from disease descriptions included in ICD billing codes.  This is proposed 
as a very quick, automated way of categorizing disease severity in currently existing 
patient databases that may be performed as an alternative to manual detailed chart review 
such as the review described in this thesis and previous AAST validation studies.  More 
centers with less resources would be able to grade their patients and be compared.  As 
AAST severity-standardized outcomes comparisons across 12 centers has been published 
as proof-of-concept (8), a more automated way of grading patients in existing registries 
will be needed to gather multicenter quality improvement metrics in the future. 
Utter et al has published a conceptual approach that has described how, in the 
language used in current ICD-10 coding descriptions, five EGS diseases can be mapped 
into four categories of severity, seven into three categories, and four into two categories.  
Furthermore, when compared to ICD-9 codes, two diseases mapped into discontinuous 
categories of grades.  Their work suggests the resolution of current ICD codes is too 
limited for accurate mapping to be accomplished solely using codes.  Furthermore, the 
increased resolution of ICD-10 codes does not comport with finer mapping of AAST 
severity grades.  Ultimately, the ability to use ICD codes to grade disease depends on 
incorporating the AAST disease descriptions into the code and is not easily achieved 
given the current complexity in ICD coding.  Nonetheless, Utter et al argues that mapping 
ICD codes to AAST grades is a good starting point for manual review (34). 
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Conclusions 
Higher grades of AAST anatomic severity were independently associated with 
significant clinical outcomes in patients with cholecystitis.  Distinctions within low grade 
disease were less significant than comparisons of low versus high grade disease.  
Enhanced granularity in the lower grades of cholecystitis may enable AAST to better 
predict outcomes in larger, multicenter patient samples with a wide range of disease.  The 
continued validation of AAST will facilitate better risk stratification and quality 
improvement in emergency general surgery. 
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